MI-CP151 was a phase 1b randomised, double-blind, placebo controlled, dose-escalation, multicentre study to evaluate various intravenous doses of sifalimumab, in adult people with dermatomyositis or polymyositis (NCT00533091). Principal trial targets have been To judge the security and tolerability